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Abstract
Background: Informed by recent studies demonstrating the central role of plasma HIV-1 RNA viral load (VL) on HIV
transmission, interventions to employ HIV antiretroviral treatment as prevention (TasP) are underway. To optimize
these efforts, evidence is needed to identify factors associated with both non-suppressed VL and HIV risk behav-
iours. Thus, we sought to assess the possible role played by exposure to correctional facilities on VL non-
suppression and used syringe lending among HIV-seropositive people who use injection drugs (PWID).
Methods: We used data from the ACCESS study, a community-recruited prospective cohort. We used longitudinal
multivariate mixed-effects analyses to estimate the relationship between incarceration and plasma HIV-1 RNA > 500
copies/mL among antiretroviral therapy (ART)-exposed active PWID and, during periods of non-suppression, the
relationship between incarceration and used syringe lending.
Results: Between May 1996 and March 2012, 657 ART-exposed PWID were recruited. Incarceration was independently
associated with higher odds of VL non-suppression (Adjusted Odds Ratio [AOR] = 1.54, 95% Confidence Interval
[95% CI]: 1.10, 2.16). In a separate multivariate model restricted to periods of VL non-suppression, incarceration was
independently associated with lending used syringes (AOR = 1.81, 95% CI: 1.03, 3.18).
Conclusions: The current findings demonstrate that incarceration is associated with used syringe lending among
active PWID with detectable plasma HIV-1 RNA. Our results provide a possible pathway for the commonly observed
association between incarceration and increased risk of HIV transmission. Our results suggest that alternatives to
incarceration of non-violent PWID and evidence-based combination HIV prevention interventions for PWID within
correctional facilities are urgently needed.
Background
Recent studies have demonstrated that plasma HIV-1
RNA viral loads (VL), at the individual, community and
population levels, likely play a central role in determin-
ing HIV transmission dynamics. First demonstrated in
studies of the role of maternal VL on the risk of peri-
natal vertical transmission [1], the link between VL and
the incidence of HIV seroconversion has since been ob-
served in observational analyses [2-4] and simulation
models [5-7], and confirmed in the landmark HPTN-052
randomized clinical trial [8].
Informed by this insight, HIV treatment as prevention
(TasP) has been adopted as a backbone of combination
HIV prevention efforts [9,10] and public health-based ef-
forts to seek, test, treat and retain (STTR) individuals in
evidence-based medical care are underway. Evidence is
now required to optimize TasP programmes in order to
maximize their impact on HIV incidence. This is espe-
cially true among people who use injection drugs, who
continue to experience high levels of HIV/AIDS-associ-
ated morbidity and mortality and account for more than
one-quarter of incident cases outside sub-Saharan Africa
[11]. Since there are concerns that TasP efforts might be
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compromised by, for example, difficulties detecting acutely-
infected individuals [1,12] or improving engagement in
the HIV clinical care cascade [2-4,13], HIV prevention in-
terventions will benefit from the identification of expo-
sures that are associated with both uncontrolled VL and
risk behaviours for onward HIV transmission (i.e., used
syringe lending).
Among people who inject drugs (PWID), exposure to
correctional facilities is common and has been con-
sistently associated with heightened risk of sharing used
syringes in custodial [14,15] and non-custodial [16] set-
tings. Although many PWID cease injection while incar-
cerated, the routine lack of sterile syringes often means
levels of syringe sharing are typically higher in correc-
tional settings than in the community [8,17,18]. As a re-
sult, prison-based HIV transmission has been reported
in the United States [9,10,19], Scotland [11,20], Australia
[21], Russia [22] and other locations [23,24]. Among
people living with HIV, exposure to correctional facilities
has been associated with sub-optimal HIV treatment in-
cluding lower access and adherence to antiretroviral
therapy (ART) [25,26]. However, we are unaware of any
study that has evaluated the possible effects of both in-
carceration on VL non-suppression and used syringe
lending among PWID living with HIV infection. Thus,
in these analyses, we sought to estimate the relationships
between incarceration and VL non-suppression and in-
carceration and used syringe lending during periods of
viremia.
Methods
To evaluate these objectives, we used data from the
AIDS Care Cohort to evaluate Exposure to Survival Ser-
vices (ACCESS), an ongoing prospective observational
cohort of illicit drug users living with HIV/AIDS in
Vancouver, British Columbia, Canada. Described in de-
tail elsewhere [3,27], recruitment for the cohort began in
May, 1996, and focused on the city’s Downtown Eastside
neighbourhood, a post-industrial area with an open drug
market and high levels of illicit drug use, poverty and
HIV infection. We used community-based recruitment
methods including targeted solicitation of areas where
PWID are known to frequent, such as harm reduction
venues, low-barrier service providers and single-room
occupancy (SRO) hotels. Individuals are eligible for in-
clusion in ACCESS if they are HIV seropositive, are
aged ≥ 18 years, have used illicit drugs other than canna-
binoids in the previous month. After individuals are
screened for inclusion and offered enrollment in the
study, they complete an informed consenting process in
a private and secure room at the study office. During
this process, the participant and a study representative
review a standardized letter which explains the study, its
hypotheses and protocols and the possible risks and
benefits of participation. Only individuals who provide
written informed consent are included in the study. At the
baseline interview and every biannual interview thereafter,
participants respond to an interviewer-administered ques-
tionnaire, are examined by a study nurse and provide
blood for serologic analyses. At recruitment, participants
provide their personal health number (PHN), a unique
and persistent identifier issued for billing and tracking
purposes to all residents of British Columbia by the
government-run universal and no-cost medical system.
All study activities were reviewed and approved by the
Providence Health Care/University of British Columbia
Research Ethics Board (REB) prior to the commence-
ment of the study. The REB reviews the study annually,
including any changes to, for example, the recruitment
process and all study instruments.
Information gathered through the interview and exam-
ination process is augmented by data on HIV treatment
and clinical outcomes through a confidential linkage with
the British Columbia Centre for Excellence in HIV/AIDS
(BCCfE), as described elsewhere [27]. The BCCfE provides
ART and related care free of charge to all individuals living
with HIV/AIDS in British Columbia. Through the linkage
a complete retrospective and prospective clinical profile,
including data on all ART dispensations, CD4+ cell counts
and plasma HIV-1 RNA viral load (PVL) observations, is
available for each participant.
In this study, we included all individuals who had re-
ceived at least one day of antiretroviral medication prior
to the baseline interview. ART-naïve individuals who initi-
ated treatment were included from the next follow-up
interview forward. Individuals without at least one CD4+
cell count and PVL observation within ± 180 days of the
baseline interview were excluded from these analyses. As
well, because our objective was to model the risk of for-
ward HIV transmission via contaminated syringes, we ex-
cluded an individual’s follow-up period if they did not
report any injection drug use in that period.
Using this analytic sample, we tested three hypotheses:
First, during any six-month follow-up period, incarcer-
ation is associated with higher odds of exhibiting detect-
able VL, independent of possible confounding factors. If
the first hypothesis is true, we will test the second hy-
pothesis: the independent relationship between incarcer-
ation and VL non-suppression is mediated by adherence
to ART. Finally, we will test the third hypothesis: incar-
ceration is associated with higher odds of used syringe
lending during periods of VL non-suppression, inde-
pendent of possible confounding factors.
In the test of the first hypothesis, the primary outcome
of interest was detectable VL in the previous six months,
defined as >500 RNA copies/mL plasma. This value was
used as it is the lowest level available throughout the
study period and is the same as previous analyses of VL
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from our setting [28,29]. HIV clinical monitoring data
was gathered using each participant’s PHN through the
confidential linkage described above and included all VL
and CD4+ measurements conducted through the study
as well as any VL/CD4+ tests conducted outside of the
study setting, for example, by a participant’s personal
physician. Thus, we were able to include all VL observa-
tions conducted in both community and correctional
settings. In the event that more than one VL observation
was conducted in the prior six months, we included the
median of all observations. The Roche Amplicor Moni-
tor assay was used to determine VL from participant
blood samples (Roche Molecular Systems, Pleasanton,
California).
The primary explanatory variable was incarceration in
a city jail, provincial prison or federal penitentiary over-
night or longer in the six month period prior to the
interview, consistent with previous studies [30,31]. To
best estimate the effect of incarceration on the likelihood
of VL non-suppression, we considered a range of sec-
ondary explanatory variables we hypothesized might
confound this relationship. These variables were: Age
(per year older); gender (female vs. male); Aboriginal an-
cestry (yes vs. no); heroin injection (≥ daily vs. < daily);
cocaine injection (≥ daily vs. < daily); crack cocaine use
(≥ daily vs. < daily); education (≥ high school diploma
vs. < high school diploma); homelessness (yes vs. no); in-
volvement in sex work (yes vs. no); binge drug use, defined
as any period of above-average drug use (yes vs. no); and
methadone maintenance therapy (yes vs. no). All of the
behavioural measures were time-updated and referred to
the six month period prior to the follow-up interview,
except for homelessness and MMT, which referred to
current status. In addition, we included four clinical vari-
ables: HIV MD experience (< 6 patients vs. ≥ 6 patients
previously treated for HIV); CD4+ cell count (per 100
cells); adherence to ART; and the presence of a protease
inhibitor (PI) in the first ART regimen (yes vs. no). As in
previous research [32,33], our physician experience vari-
able was based on how many individuals the participant’s
physician had previously enrolled in the HIV/AIDS treat-
ment registry at the time of initiating the participant on
their first dose of ART. This time-invariant measure was
dichotomized at six patients, as before [32,33]. We have
previously demonstrated that this measure independently
predicts VL suppression following ART initiation [33]. As
with our measure of VL, we included all CD4+ observa-
tions conducted by study staff or personal physicians and
calculated a mean of all observations in the previous six
months or, if no observations were made, the most recent
measure. The measure of adherence to antiretroviral ther-
apy was the product of the number of days dispensed anti-
retroviral therapy in the previous 180 days over the
number of days eligible in the previous 180 days,
dichotomized at above or below 95%. We have used this
validated measure of pharmacy refill extensively in previ-
ous research [30,34] and have shown it reliably predicts
VL suppression [1,35-37] and survival [2-4,32].
To determine the final set of secondary explanatory
variables to include in the multivariate model, we first
estimated bivariate statistics for the relationships be-
tween VL non-suppression and each explanatory vari-
able of interest over the entire study period using
generalized linear mixed-effects analysis. This form of
regression analysis was used to account for the correl-
ation between variables gathered over time from the
same individual and, through the use of random inter-
cepts, the unobserved variation in the likelihood of non-
suppression within each individual [38].
Next, using an a priori-defined procedure first de-
scribed by Maldonado and Greenland [8,39], we con-
structed a multivariate model including the primary
explanatory variable and all secondary explanatory vari-
ables with p-values < 0.4 in bivariate analyses, noting the
value of the β coefficient associated with incarceration.
We then fit a series of multivariate models each with
one secondary explanatory variable removed, always not-
ing the value of the β coefficient associated with incar-
ceration. After fitting all possible models, we removed
the secondary explanatory variable corresponding to the
smallest relative change in the β coefficient for incar-
ceration from further consideration and repeated the
process. This continued until the smallest change from
the full model exceeded 5%, thus preserving secondary
explanatory variables with a greater relative impact in
the relationship between incarceration and the likelihood
of non-suppressed VL. This technique has been used in
many studies to estimate the independent effect of a
variable on an outcome of interest [9,10,30,40,41]. To
account for HIV disease progression, and, in the early
HAART era, the phenomenon of individuals discontinu-
ing therapy at high CD4+ counts to relieve treatment
side-effects, we included CD4+ cell count as an explana-
tory covariate in all multivariate models.
To test our second hypothesis, that adherence to ART
mediated the relationship between incarceration and VL
non-suppression, we calculated the Sobel test statistic,
using β and Standard Errors from regression models
of incarceration, adherence and VL non-suppression
[11,42,43], as in a previous study of age, adherence and
VL suppression [12,44].
To test our third hypothesis, that incarceration was as-
sociated with a greater risk of used syringe lending
among individuals experiencing viremia, we constructed
a second multivariate model using the procedure de-
scribed above. The outcome of interest was reporting
lending used syringes in the previous six month period,
as described in previous analyses [13,45]. The primary
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explanatory variable was incarceration in the previous
six months. Secondary explanatory variables considered
were: Age (per year older); gender (female vs. male);
Aboriginal ancestry (yes vs. no); homelessness (yes vs. no);
education (≥ high school diploma vs. < high school dip-
loma); formal employment (yes vs. no); sex work (yes vs.
no); heroin injection (≥ daily vs. < daily); cocaine injection
(≥ daily vs. < daily); crack cocaine use (≥ daily vs. < daily);
binge drug use (yes vs. no); MMT (yes vs. no); CD4+ cell
count (per 100 cells/mL). We also included a variable for
the year of observation (> 2001 vs. ≤ 2001), as we have
previously described how local policy changes beginning
in 2001, including increasing the supply of syringes, re-
moving the requirement individuals return one used syr-
inge for every new syringe received and decentralizing the
distribution of syringes, were associated with a reduction
in HIV incidence [14,15,46].
As above, we calculated bivariate relationships between
syringe lending and each secondary explanatory variable,
retaining explanatory variables with p-values < 0.4 for in-
clusion in the full multivariate model. Using an a priori
defined protocol, we fit a series of reduced multivariate
models to identify secondary explanatory variables with
greater relative influence on the effect of incarceration on
used syringe lending. As a last step, we fit the final multi-
variate model to best estimate the independent effect of
incarceration on used syringe lending among individuals
with non-suppressed VL.
Results
Between May, 1996 and March, 2012, 1,036 HIV-seropositive
illicit drug users were recruited and completed at least
one interview. Of these, 217 (20.9%) were ART-naïve at
recruitment and throughout the study and were excluded.
Of the remaining 819, 783 (95.6%) had complete clinical
data within 180 days of recruitment and 657 (80.2%) had
at least one period of active injection drug use and were
included in these analyses.
The 657 participants completed 3929 baseline or follow-
up interviews, equal to 1965 person-years of observation.
The median number of interviews completed was 4 (inter-
quartile range [IQR]: 2, 8) per participant, or 2.4 (0.6, 4.8)
per participant. Among the 657 individuals, 455 (69.3%)
had at least one period of VL non-suppression. In 3929 in-
terviews during the study period, 198 interviews contained
reports of used syringe lending from 111 participants. For
each interview, the median number of days since a CD4+
cell count observation was 58 days (IQR: 26, 127) and
3798 (96.7%) interviews occurred within 365 days of a
CD4+ cell count observation.
This analytic sample was comprised of 228 (34.7%)
women and 245 (37.3%) individuals reporting Aboriginal
ancestry. Select socio-demographic, behavioural, struc-
tural and clinical characteristics of the participants at
the baseline interview stratified by VL suppression are
presented in Table 1.
The first hypothesis evaluated was that incarceration
was associated with VL non-suppression independent of
relevant confounders. There were 8,284 VL observations
made over the entire study period, or a median of 9
(IQR: 4, 17) per participant, of which 3,314 (40.0%) indi-
cated 500 HIV-1 RNA copies or greater per mL plasma.
Non-suppression of VL was observed in 1972 (50.2%) of
3929 interviews. The crude and adjusted longitudinal es-
timates of the odds of VL non-suppression are presented
in Table 2. In addition, in a sub-analysis, we observed a
significant relationship between VL non-suppression and
reporting used syringe lending (OR = 1.99, 95% CI: 1.30,
3.05, p = 0.002).
Over the entire study period, incarceration was common,
with 594 (15.1%) of all interviews including a report of at
least one incarceration event in the previous six months.
Among all participants, 235 (35.8%) were incarcerated at
least once; among individuals ever incarcerated, the median
number of periods including incarceration was 2 (IQR = 1,
3). Individuals incarcerated during the previous six months
had at least double the odds of VL non-suppression com-
pared to non-incarcerated individuals (OR = 2.00, 95%
CI: 1.47, 2.72, p < 0.001). In a multivariate model adjusted
for age, CD4+ cell count, engagement in MMT, heroin in-
jection and homelessness, incarceration was independ-
ently associated with higher odds of VL non-suppression
(Adjusted Odds Ratio = 1.54, 95% CI: 1.10, 2.16, p = 0.011).
In a sub-analysis, we repeated the protocol adding year
of observation to the model-building protocol (results
not shown). Our results were not significantly different.
The second hypothesis was that ART adherence medi-
ated the relationship between incarceration and VL non-
suppression. A statistical test of mediation was significant
(Sobel test = 4.09, p < 0.001).
The third hypothesis was that incarceration was asso-
ciated with used syringe lending during periods of VL
non-suppression, independent of potential confounders.
Of the 198 interviews with a report of used syringe lend-
ing, 132 (66.7%) occurred during periods of VL non-
suppression. Crude and adjusted longitudinal estimates
of factors associated with used syringe lending among
455 active PWID with non-suppressed VL are presented
in Table 3. Compared to non-incarcerated individuals,
individuals reporting incarceration had almost double
the odds of used syringe lending (OR = 1.76, 95% CI: 1.01,
3.05, p = 0.046). In the multivariate model, incarceration
was independently associated with lending used syringes
(AOR = 1.81, 95% CI: 1.03, 3.18, p = 0.038).
Discussion
In these analyses of data from a long-running community-
recruited cohort of active PWID, we observed a high level
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Table 1 Baseline characteristics of 657 ART-exposed active PWID in Vancouver, Canada stratified by plasma HIV-1 RNA
viral load (VL) non-suppression, 1996 – 2012
Characteristic VL suppressed VL non-suppressed Odds ratio 95% CI2 p-value
153 (23.3) 504 (76.7)
n (%) n (%)
Incarceration3
No 227 (87.3) 312 (78.6) 1.00
Yes 33 (12.7) 85 (21.4) 1.87 1.21, 2.90 0.005
Age
Median (IQR) 45.3 (39.5 – 50.7) 37.9 (33.1 – 43.9) 0.98 0.98, 0.98 < 0.001
Gender
Male 191 (73.5) 238 (60.0) 1.00
Female 69 (26.5) 159 (40.0) 1.85 1.32, 2.60 < 0.001
Aboriginal ancestry
No 172 (66.2) 240 (60.5) 1.00
Yes 88 (33.8) 157 (39.5) 1.28 0.92, 1.77 0.161
Heroin injection
< Daily 230 (88.5) 293 (73.8) 1.00
≥ Daily 30 (11.5) 104 (26.2) 2.72 1.75, 4.23 < 0.001
Cocaine injection
< Daily 227 (87.3) 289 (72.8) 1.00
≥ Daily 33 (12.7) 108 (27.2) 2.57 1.68, 3.94 < 0.001
Crack cocaine use
< Daily 164 (63.1) 291 (73.3) 1.00
≥ Daily 96 (36.9) 106 (26.7) 0.62 0.44, 0.87 0.007
Education
< High school diploma 136 (52.3) 252 (63.5) 1.00
≥ High school diploma 124 (47.7) 145 (36.5) 0.63 0.46, 0.87 0.005
Homeless
No 243 (93.5) 352 (88.7) 1.00
Yes 17 (6.5) 45 (11.3) 1.83 1.02, 3.27 0.041
Sex work3
No 235 (90.4) 328 (82.6) 1.00
Yes 25 (9.6) 69 (17.4) 1.98 1.21, 3.22 0.006
HIV MD experience
≥ 6 patients 223 (85.8) 320 (80.6) 1.00
< 6 patients 37 (14.2) 77 (19.4) 1.45 0.95, 2.22 0.093
PI in first ART regimen
No 160 (61.5) 238 (59.9) 1.00
Yes 100 (38.5) 150 (40.1) 1.07 0.78, 1.47 0.744
CD4+ cells (per 100/mm3)
Median (IQR) 3.6 (2.4 – 4.9) 2.6 (1.5 – 4.0) 0.95 0.94, 0.97 < 0.001
ART adherence
≤ 95% 102 (39.2) 377 (95.0) 1.00
> 95% 158 (60.8) 20 (5.0) 0.03 0.02, 0.06 < 0.001
295% Confidence Interval (95% CI).
3Refers to 180 day period prior to baseline interview.
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of VL non-suppression. Uncontrolled VL was observed in
more than half of all baseline and follow-up interview pe-
riods; more than two-thirds of all participants experienced
at least one period of uncontrolled VL. In a multivariate
model adjusted for a range of clinical, behavioural and
structural correlates of non-suppression, incarceration
was independently associated with greater odds of VL
non-suppression. In a second multivariate model among
PWID at risk of onward transmission, incarceration was
independently associated with a greater likelihood of used
syringe lending.
As with all observational studies, we cannot exclude
the possibility that the observed association between
incarceration and VL non-suppression is influenced by re-
sidual confounding. However, a number of lines of evi-
dence support a causal relationship between exposure to
correctional facilities and elevated viral load. Although
correctional systems select for populations marked by
Table 2 Crude and adjusted longitudinal estimates of the odds of plasma HIV-1 RNA viral load non-suppression among
657 ART-exposed active PWID, Vancouver, 1996 – 2012
Characteristic OR1 95% CI2 p-value AOR3 95% CI p-value
Incarceration4
Yes vs. no 2.00 1.47 – 2.72 < 0.001 1.54 1.10, 2.16 0.011
Age
Per year 0.90 0.87 – 0.92 < 0.001 0.91 0.88, 0.94 < 0.001
Gender
Female vs. male 1.69 1.07 – 2.67 0.024
Aboriginal ancestry
Yes vs. no 1.35 0.86 – 2.11 0.189
Homeless5
Yes vs. no 2.38 1.59 – 3.58 < 0.001 1.83 1.19, 2.82 0.006
Education
≥HS vs < HS 0.89 0.66 – 1.22 0.476
Employment4
Yes vs. no 0.48 0.25 – 0.92 0.028
Heroin injection4
≥ Daily vs. < daily 2.76 2.07 – 3.69 < 0.001 2.09 1.53, 2.87 <0.001
Cocaine injection4
≥ Daily vs. < daily 1.52 1.18 – 1.97 0.001
Crack cocaine use4
≥ Daily vs. < daily 1.37 1.06 – 1.76 0.015
Binge drug use4
Yes vs. no 1.09 0.88 – 1.36 0.426
MMT5
Yes vs. no 0.46 0.35 – 0.59 < 0.001 0.52 0.39, 0.70 < 0.001
Sex work4
Yes vs. no 2.21 1.47 – 3.33 < 0.001
HIV MD experience
< 6 patients vs. ≥ 6 1.93 1.08 – 3.46 0.026
PI in first ART regimen
Yes vs. no 1.06 0.68 – 1.67 0.794
CD4+ cell count4
Per 100 cells/mL 0.48 0.44 – 0.53 < 0.001 0.51 0.47, 0.56 < 0.001
ART adherence4
≥ 95% vs < 95% 0.03 0.02 – 0.04 < 0.001
1Odds Ratio; 295% Confidence Interval; 3Adjusted Odds Ratio; 4Refers to the six month period prior to follow-up; 5Refers to current status.
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high levels of various risks for sub-optimal HIV treatment
outcomes, such as more severe addiction, our findings
persisted even after they were adjusted for a range of sig-
nificant factors, including homelessness, high-intensity
illicit drug use, age and immunologic status. Consistent
with the hypothesis that incarceration may contribute
to antiretroviral interruption, prior studies of virally-
suppressed PWID on ART in Vancouver, BC [17,18,31],
and Baltimore, Maryland [19,26] identified incarceration
as a strong independent risk factor for virologic rebound.
Second, our finding that incarceration-related VL non-
suppression is driven by poorer ART adherence is consist-
ent with a range of previous analyses. For example, we
recently demonstrated that the number of incarceration
episodes experienced longitudinally was strongly associ-
ated with non-adherence to prescribed treatment in a
dose-dependent fashion [20,30], in line with previous work
isolating transfer between correctional/non-correctional
environments [21,25] and prison-related HIV stigma as
barriers to optimal ART adherence [22,47].
Our findings should be considered in light of increas-
ing efforts to implement HIV treatment as prevention.
Globally, HIV incidence among PWID remains high des-
pite a range of effective evidence-based HIV prevention
interventions, including sterile syringe distribution, opi-
oid substitution therapies and supervised injection facil-
ities [25,26,48]. Although these interventions are, by and
large, simple and cost-effective, coverage remains low in
Table 3 Crude and adjusted longitudinal estimates of the odds of used syringe lending among 455 ART-exposed active
PWID with unsuppressed plasma HIV-1 RNA viral loads, Vancouver, Canada, 1996 – 2012
Characteristic OR1 95% CI2 p-value AOR3 95% CI p-value
Incarceration4
Yes vs. no 1.76 1.01 – 3.05 0.046 1.81 1.03, 3.18 0.038
Age5
Per year 1.03 0.94 – 1.13 0.515
Gender
Female vs. male 1.09 0.23 – 5.08 0.916
Aboriginal ancestry
Yes vs. no 0.30 0.09 – 0.96 0.043
Homeless5
Yes vs. no 1.18 0.40 – 3.47 0.759
Education5
≥ HS vs. < HS 0.82 0.36 – 1.86 0.635
Employment4
Yes vs. no 3.55 0.53 – 23.99 0.193
Heroin injection4
≥ Daily vs. < daily 0.77 0.35 – 1.70 0.520
Cocaine injection4
≥ Daily vs. < daily 1.27 0.64 – 2.51 0.500
Crack cocaine use4
≥ Daily vs. < daily 0.86 0.40 – 1.84 0.691
Binge drug use4
Yes vs. no 1.28 0.72 – 2.29 0.397
MMT5
Yes vs. no 1.27 0.58 – 2.79 0.553
Sex work4
Yes vs. no 1.72 0.67 – 4.44 0.259
Year of observation
> 2001 vs ≤ 2001 0.11 0.03 – 0.36 < 0.001 0.15 0.08, 0.29 < 0.001
CD4+ cell count
Per 100 cells/mL 1.17 0.95 – 1.44 0.142
1Odds Ratio; 295% Confidence Interval; 3Adjusted Odds Ratio; 4Refers to the six month period prior to follow-up; 5Refers to current status.
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many jurisdictions as criminal justice-based interven-
tions remain the dominant response to injection drug
use [3,23,27]. There is a clear danger that this dynamic
will be repeated and the effect of TasP-based efforts to
curb elevated HIV incidence among PWID will be com-
promised by incarceration-related barriers to HIV treat-
ment. To date, there has been little discussion of the
effect of the criminalization of PWID on TasP imple-
mentation as concerns have focused on behavioural fac-
tors associated with adherence [27,49]. Our evidence of
the role played by incarceration on VL and HIV risk be-
haviours is an example of why structural dynamics must
be considered in all combination HIV prevention inter-
ventions, including TasP [30,31,50,51].
As the HIV/AIDS pandemic enters its fourth decade,
correctional facilities remain important foci of HIV inci-
dence and prevalence, especially in Canada, the United
States, areas of the former Soviet Union and south and
southeast Asia [24,32,52,53]. Although data is incom-
plete, the prevalence of HIV infection is typically several
times higher in detained populations compared to the
general population and surpasses 10% in several jurisdic-
tions [32,52]. Although some studies have demonstrated
impressive clinical gains for people who are incarcerated
and living with HIV/AIDS [30,34,54-56], and studies are
underway of STTR efforts within a number of correc-
tional systems in the United States [57], several prison-
related barriers to optimal HIV treatment are common
in many jurisdictions, including sub-standard healthcare
facilities, poor continuity of care between correctional
and non-correctional health systems, lack of care for
HIV-related co-morbidities such as addiction and an em-
phasis on public security over public health [24,58,59]. In
Canada, although the most recently released infectious
disease surveillance data from 2007 reported that 1.6
percent of male and 4.7 percent of female individuals
detained in the federal penitentiary system in 2007 were
living with HIV/AIDS [60], we are unaware of any formal
efforts to prevent prison-based HIV transmission through
STTR initiatives. Further, officials in many settings have
consistently refused to implement any prison-based needle
exchange programmes, despite clear evidence of ongoing
illicit drug use and syringe sharing within prisons and re-
peated calls by people who use injection drugs, physicians,
legal experts and advocates [61,62]. Our current findings
suggest that investments in HIV prevention and treatment
efforts may be undercut by the lack of HIV prevention
and treatment in prisons, especially among people who
use injection drugs.
This research has some limitations. First, no registries
of HIV-seropositive PWID exist and thus our analytic
sample cannot be seen as representative of all HIV-
positive PWID in this setting or others. Second, as men-
tioned above, we cannot exclude the possible existence
of unmeasured confounding, however we sought to mini-
mize its influence by multivariate modeling and the use of
data a large and long-running community-recruited pro-
spective cohort of illicit drug users. Third, our measure of
incarceration was based on self-report as administrative
data was unavailable. Fourth, we were unable to determine
whether VL measurements occurred prior to, during or
following an incarceration event. Our primary outcome of
interest was ascertained through data from the local com-
prehensive provider of HIV clinical monitoring in a setting
with no financial barriers to healthcare and we are un-
aware of any reason individuals might differentially report
incarceration history based on their viral load status.
Conclusions
To conclude, we used data from an ongoing prospective
cohort of HIV-seropositive PWID with comprehensive
clinical monitoring data and found incarceration was an
independently associated with both non-suppression of
PVL and used syringe sharing. To our knowledge, this is
the first study to exploit recent advances in knowledge
of VL and risk behaviours to model the risks of onward
HIV transmission among people living with HIV infection.
Our findings re-emphasize the importance of considering
the structural determinants of HIV transmission, espe-
cially in the new era of combination HIV prevention inter-
ventions involving traditional HIV prevention strategies
with the use of antiretroviral therapy. They also highlight
the urgent need to identify and remove incarceration-
related barriers to effective HIV treatment to address
persistently high levels of HIV incidence and HIV/
AIDS-related morbidity and mortality among people
who use injection drugs. Finally, our results suggest that
alternatives to incarceration of non-violent PWID and
evidence-based combination HIV prevention interven-
tions for PWID within correctional facilities are urgently
needed.
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